今年6月7日,渤健(Biogen)基于β-淀粉样蛋白假说而开发的第一款用于治疗AD的单克隆抗体药物Aduhelm历经波折,终获得美国FDA批准上市,是近20年来AD领域首款新疗法...查看全文
$Trident(TDAC)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-11 AccNo: 0001062993-19-000588 Size: 23 KB 网页链接
$Trident(TDAC)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-05 AccNo: 0001393825-19-000101 Size: 61 KB 网页链接
$Trident Acquisitions Corp(TDAC)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2018-11-09 AccNo: 0001615774-18-012418 Size: 1 MB 网页链接
$Trident Acquisitions Corp(TDAC)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2018-11-09 AccNo: 0001615774-18-012418 Size: 1 MB 网页链接
$Trident Acquisitions Corp(TDAC)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2018-08-13 AccNo: 0001615774-18-007916 Size: 1 MB 网页链接
$Trident Acquisitions Corp(TDAC)$ CORRESP [Cover] - Correspondence Filed: 2018-05-24 AccNo: 0001615774-18-004365 Size: 7 KB 网页链接
$Trident Acquisitions Corp(TDAC)$ CORRESP [Cover] - Correspondence Filed: 2018-05-24 AccNo: 0001615774-18-004358 Size: 9 KB 网页链接
$Trident Acquisitions Corp(TDAC)$ CORRESP [Cover] - Correspondence Filed: 2018-05-24 AccNo: 0001615774-18-004365 Size: 7 KB 网页链接
$Trident Acquisitions Corp(TDAC)$ CORRESP [Cover] - Correspondence Filed: 2018-05-24 AccNo: 0001615774-18-004358 Size: 9 KB 网页链接